Amgen's (AMGN) new drug Prolia for treatment of osteoporosis wins approval for sale in Europe. GlaxoSmithKline (GSK) will market the drug, throwing its weight behind a product that industry analysts expect to make billions of dollars in annual sales. AMGN +1%, GSK +1.7% premarket.
Market Data 
Markets 
AI
